Dyadic International (DYAI) Common Equity (2017 - 2026)
Dyadic International's (DYAI) quarterly Common Equity came in at -$407732.0 in Q1 2026, down 144.15% year-over-year from $923611.0 in Q1 2025, and down 100.41% quarter-over-quarter from $100.0 million in Q4 2025.
Analysis
Dyadic International (DYAI) Common Equity (2017 - 2026) Analysis & Trends
Dyadic International has disclosed Common Equity across 10 years of filings, most recently posting -$407732.0 for Q1 2026.
- In Q1 2026, Common Equity fell 144.15% year-over-year to -$407732.0; the TTM figure through Mar 2026 stood at -$407732.0 (down 144.15% YoY), while the FY2025 annual figure was $100.0 million, up 3948.11% from the prior year.
- Common Equity came in at -$407732.0 for Q1 2026 at Dyadic International, down from $100.0 million in the prior quarter.
- In the past five years, Common Equity ranged from a high of $100.0 million in Q4 2025 to a low of -$529701.0 in Q2 2025.
- Average Common Equity over 5 years is $11.9 million, with a median of $5.9 million recorded in 2023.
- Year-over-year, Common Equity surged 3948.11% in 2025 and plunged 144.15% in 2026.
- Over 5 years, Common Equity stood at $11.1 million in 2022, then sank by 46.98% to $5.9 million in 2023, then plunged by 57.98% to $2.5 million in 2024, then surged by 3948.11% to $100.0 million in 2025, then tumbled by 100.41% to -$407732.0 in 2026.
- Per Business Quant data, the three most recent Common Equity figures were -$407732.0 in Q1 2026, $100.0 million in Q4 2025, and $2.6 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 11.69 Bn |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | 11.83 Bn |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | 20.25 Bn |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 31.71 Bn |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | 8.42 Bn |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | 6.76 Bn |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | 1.35 Bn |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | 18.85 Bn |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | 4.92 Bn |
| 10 | Dyadic International | 17.78 Mn | 9.82 Mn | - | -407,732.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2026 | -407,732.00 |
| Dec 31, 2025 | 100.00 Mn |
| Sep 30, 2025 | 2.61 Mn |
| Jun 30, 2025 | -529,701.00 |
| Mar 31, 2025 | 923,611.00 |
| Dec 31, 2024 | 2.47 Mn |
| Sep 30, 2024 | 3.41 Mn |
| Jun 30, 2024 | 3.17 Mn |
| Mar 31, 2024 | 4.52 Mn |
| Dec 31, 2023 | 5.88 Mn |
| Sep 30, 2023 | 7.65 Mn |
| Jun 30, 2023 | 8.99 Mn |
| Mar 31, 2023 | 10.80 Mn |
| Dec 31, 2022 | 11.09 Mn |
| Sep 30, 2022 | 12.61 Mn |
| Jun 30, 2022 | 13.56 Mn |
| Mar 31, 2022 | 16.39 Mn |
| Dec 31, 2021 | 18.39 Mn |
| Sep 30, 2021 | 21.90 Mn |
| Jun 30, 2021 | 23.16 Mn |